Summary of Financial Reorganization Plan May 6, 2025 Strategic Action to Eliminate $1.15 Billion of Debt and Strengthen Financial Position The decisive actions we're taking today, with the overwhelming support of our lenders and noteholders, will give us the flexibility to accelerate innovation, reinvest in our members, and lead with authority in a rapidly evolving weight management landscape. As the $1.6B Existing $465M Pro forma ~70% Reduction Debt conversation around weight shifts toward long- term healt ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

WW International (WW) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.06 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of -80.77%. A quarter ago, it was expected that this weight- loss program operator would post a loss of $0.10 per share when it actually produced earnings of $0.32, delivering a surprise of 420%. Over the last four quarters, ...

WW International (WW) Update / Briefing May 06, 2025 06:00 PM ET Speaker0 Good day and welcome to the Weight Watchers Investor Conference Call. All participants will be in listen only mode. As a reminder, today's conference is being recorded. I would now like to turn the conference over to David Helderman, Director, Investor Relations. Please go ahead. Speaker1 Thank you for joining us today for the Weight Watchers investor conference call. Earlier this afternoon, we issued a press release reporting our fir ...

Operations continue with no impact to its more than three million members worldwide Positions the Company to execute its transformation strategy, focused on enhancing its digital and member experience and expanding its telehealth business which achieved 57% year-over-year revenue growth in Q1 2025 Enters comprehensive agreement with lenders and noteholders to significantly reduce its debt obligations and bolster financial flexibility Expects reorganization plan to be confirmed in approximately 40 days and ...

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, announced that it will host an investor conference call today May 6, 2025, at 6:00 p.m. ET. During the call, Tara Comonte, President and Chief Executive Officer, and Felicia DellaFortuna, Chief Financial Officer, will discuss an agreement with the Company’s lenders and noteholders that will significantly reduce debt obligations that is cur ...

Exhibit 99.1 WW International, Inc. Announces First Quarter 2025 Results NEW YORK (May 6, 2025) – WW International, Inc. (NASDAQ: WW) ("WeightWatchers," "WW," or the "Company") today announced its results for the first quarter of fiscal 2025 ended March 29, 2025. "We are making progress on our strategic priorities with continued momentum in our Clinical business, while laying the foundation for long-term, sustainable growth," said Tara Comonte, President and CEO. "As the weight management landscape evolves, ...

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) ("WeightWatchers," "WW," or the "Company") today announced its results for the first quarter of fiscal 2025 ended March 29, 2025. "We are making progress on our strategic priorities with continued momentum in our Clinical business, while laying the foundation for long-term, sustainable growth," said Tara Comonte, President and CEO. "As the weight management landscape evolves, we believe our unique combination of science-backed be ...

Core Insights - WeightWatchers has announced a pharmacy integration with Gifthealth to enhance access to Zepbound® for its clinic members [1][2] - The integration aims to streamline the fulfillment process and improve medication visibility for eligible members [2][3] Company Overview - WeightWatchers is a leader in science-backed weight management, providing a holistic model of care that includes clinical interventions and community support [4] - The company has been transforming lives for over 60 years, empowering millions of members to build healthy habits [4] Integration Details - The integration with Gifthealth allows for real-time prescription tracking and streamlined access to Zepbound® vials for self-pay patients without insurance [2][3] - Zepbound® usage among WeightWatchers Clinic members has increased significantly, with 33% currently using it and prescriptions for Zepbound vials rising over 100% recently [3] Clinical Impact - A study of 3,260 WeightWatchers Clinic patients showed an average weight loss of 21% at 12 months, indicating the effectiveness of combining GLP-1 medications like Zepbound with WeightWatchers' lifestyle support [3]

Core Viewpoint - WW International, known as WeightWatchers, is preparing to file for bankruptcy to transfer control of the business to its creditors, with shares plummeting nearly 59% to 18 cents [1]. Company Summary - The company has struggled to remain relevant due to the rise of effective weight-loss drugs like Novo Nordisk's Wegovy, which provide quicker solutions to obesity [2]. - WeightWatchers is currently negotiating with lenders and bondholders, a process that is not related to market conditions or tariffs [3]. - The firm, which previously offered nutrition and behavior-change programs, acquired the subscription-based telehealth platform Sequence in 2023 to expand into obesity drug prescriptions [3]. - WeightWatchers' stock, which peaked at $100 in 2018, has significantly declined due to revenue drops, liquidity issues, and the departure of celebrity shareholder Oprah Winfrey from its board [4]. - The company has also faced challenges from competing weight-loss drugs like Ozempic [6].